Treatment Considerations and Pharmacist Collaborative Care in Diabetic Ketoacidosis Management

Simple item page
dc.contributor.authorAlgarnien_US
dc.contributor.authorAlanood.en_US
dc.date.accessioned2023-06-17T07:12:37Z
dc.date.available2023-06-17T07:12:37Z
dc.date.issued2022-10
dc.description.abstractDiabetic ketoacidosis (DKA) is a medical emergency caused by the lack of insulin. Metabolic acidosis, hyperglycemia, and ketoacidosis are its defining features. Insulin deficiency can cause DKA either in the presence or absence of a triggering event causing a chain of pathophysiological changes. Normalizing volume status, hyperglycemia, electrolytes, and ketoacidosis are the objectivesof DKA treatment. While hospital pharmacists are involved in managing DKA, community or ambulatory care pharmacists can help to prevent DKA. Depending on the particular field of practice, a p harmacist’s engagement in DKA may involve a number of factors. Inpatient pharmacists are in a good position to help with the acute care of DKA. Because they can recognize patients who are at risk for DKA due to factors including medication nonadherence or insulin pump failure, pharmacists in the community or ambulatory-care environment play a crucial role in its prevention. When a patient finds it challenging to navigate prescription plan coverage or a lack of coverage, community pharmacists can help them obtain insulin. Regardless of the professional environment, patient education is essential. Every pharmacist has the ability to give DKA patients thorough medication education that emphasizes the value of adhering to their drug schedule, addresses any obstacles that may occur, and teaches patients how to correctly monitor their blood glucose levels. Studies showed that pharmacists’ medication counseling and treatment monitoring could improve adherence to insulin medication. The aim of this review is to provide evidence that pharmacists can contribute to optimizing medication adherence and decrease the incidence of DKA.en_US
dc.identifier.affiliationsPharmacology and Toxicology Department, Pharmacy College, Umm Al-Qura University, Makkah, Saudi Arabiaen_US
dc.identifier.citationAlgarni, Alanood.. Treatment Considerations and Pharmacist Collaborative Care in Diabetic Ketoacidosis Management. Journal of Pharmacology and Pharmacotherapeutics. 2022 Oct; 13(3): 215–221en_US
dc.identifier.issn0976-500X
dc.identifier.issn0976-5018
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216063
dc.languageenen_US
dc.publisherSAGE Publicationsen_US
dc.relation.issuenumber3en_US
dc.relation.volume13en_US
dc.source.urihttps://doi.org/10.1177/0976500X221128643en_US
dc.subjectPharmacist-roleen_US
dc.subjectdiabetic ketoacidosis treatmenten_US
dc.subjecttype 1 diabetesen_US
dc.subjectmedication adherence and non-complianceen_US
dc.titleTreatment Considerations and Pharmacist Collaborative Care in Diabetic Ketoacidosis Managementen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JPP2022v13n3p215.pdf
Size:
697.26 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmacology and Pharmacotherapeutics